-
公开(公告)号:US07098024B2
公开(公告)日:2006-08-29
申请号:US10684656
申请日:2003-10-15
申请人: Koji Nagai , Nakako Arao , Kinya Souda , Kazuma Kamigiri , Masamichi Mori , Nobuaki Shindo , Haruo Seto , Kazuo Shin-Ya
发明人: Koji Nagai , Nakako Arao , Kinya Souda , Kazuma Kamigiri , Masamichi Mori , Nobuaki Shindo , Haruo Seto , Kazuo Shin-Ya
CPC分类号: C07K5/0205 , A61K35/00 , A61K38/00
摘要: This invention relates to a novel compound which has a cytotoxic activity and TGF-β like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.
-
公开(公告)号:US06670326B1
公开(公告)日:2003-12-30
申请号:US09889303
申请日:2001-07-13
申请人: Koji Nagai , Nakako Arao , Kinya Souda , Kazuma Kamigiri , Masamichi Mori , Nobuaki Shindo , Haruo Seto , Kazuo Shin-Ya
发明人: Koji Nagai , Nakako Arao , Kinya Souda , Kazuma Kamigiri , Masamichi Mori , Nobuaki Shindo , Haruo Seto , Kazuo Shin-Ya
IPC分类号: C07K512
CPC分类号: C07K5/0205 , A61K35/00 , A61K38/00
摘要: This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.
摘要翻译: 本发明涉及对人癌细胞具有细胞毒活性和TGF-β样活性并可用作抗肿瘤剂的新型化合物和含有该化合物的药物组合物。
-
公开(公告)号:US20050209134A1
公开(公告)日:2005-09-22
申请号:US10525717
申请日:2003-08-28
申请人: Koji Nagai , Masatoshi Taniguchi , Nobuaki Shindo , Yoh Terada , Masamichi Mori , Nobuaki Amino , Ken-ichi Suzumura , Isao Takahashi , Mitsuo Amase
发明人: Koji Nagai , Masatoshi Taniguchi , Nobuaki Shindo , Yoh Terada , Masamichi Mori , Nobuaki Amino , Ken-ichi Suzumura , Isao Takahashi , Mitsuo Amase
CPC分类号: C07K5/0205 , A61K38/00 , C07K11/00
摘要: The present invention relates to a novel compound which is useful as an agent for prevention and treatment of diseases associated with HDAC, in particular, tumor or cell proliferative diseases. The depsipeptide compound or its pharmaceutically acceptable salt of the present invention has a good HDAC inhibitory activity and an inhibitory activity of cell proliferation against human cancer cells and, therefore, is useful in treatment and improvement of diseases and pathogenic conditions associated with histone acetylation, in particular, tumor or cell proliferative diseases.
摘要翻译: 本发明涉及一种新型化合物,其可用作预防和治疗与HDAC相关疾病,特别是肿瘤或细胞增殖性疾病的药剂。 本发明的前肽化合物或其药学上可接受的盐具有良好的HDAC抑制活性和对人癌细胞的细胞增殖的抑制活性,因此可用于治疗和改善与组蛋白乙酰化有关的疾病和病原性病症 特别是肿瘤或细胞增殖性疾病。
-
公开(公告)号:US07098186B2
公开(公告)日:2006-08-29
申请号:US10525717
申请日:2003-08-28
申请人: Koji Nagai , Masatoshi Taniguchi , Nobuaki Shindo , Yoh Terada , Masamichi Mori , Nobuaki Amino , Ken-ichi Suzumura , Isao Takahashi , Mitsuo Amase
发明人: Koji Nagai , Masatoshi Taniguchi , Nobuaki Shindo , Yoh Terada , Masamichi Mori , Nobuaki Amino , Ken-ichi Suzumura , Isao Takahashi , Mitsuo Amase
CPC分类号: C07K5/0205 , A61K38/00 , C07K11/00
摘要: The present invention relates to a novel compound which is useful as an agent for prevention and treatment of diseases associated with HDAC, in particular, tumor or cell proliferative diseases. The depsipeptide compound or its pharmaceutically acceptable salt of the present invention has a good HDAC inhibitory activity and an inhibitory activity of cell proliferation against human cancer cells and, therefore, is useful in treatment and improvement of diseases and pathogenic conditions associated with histone acetylation, in particular, tumor or cell proliferative diseases.
摘要翻译: 本发明涉及一种新型化合物,其可用作预防和治疗与HDAC相关疾病,特别是肿瘤或细胞增殖性疾病的药剂。 本发明的前肽化合物或其药学上可接受的盐具有良好的HDAC抑制活性和对人癌细胞的细胞增殖的抑制活性,因此可用于治疗和改善与组蛋白乙酰化有关的疾病和病原性病症 特别是肿瘤或细胞增殖性疾病。
-
公开(公告)号:USD334990S
公开(公告)日:1993-04-20
申请号:US751697
申请日:1991-08-29
-
公开(公告)号:US20130137111A1
公开(公告)日:2013-05-30
申请号:US13812356
申请日:2011-07-22
申请人: Nobuaki Shindo , Kouichi Nishimura , Yorikata Sano , Makoto Asaumi , Aya Yamanaka , Takashi Futami , Tatsuya Kawase
发明人: Nobuaki Shindo , Kouichi Nishimura , Yorikata Sano , Makoto Asaumi , Aya Yamanaka , Takashi Futami , Tatsuya Kawase
IPC分类号: C12Q1/68
CPC分类号: C12Q1/6886 , C12Q2525/155 , C12Q2600/118 , G01N33/57484
摘要: It was found that a new fusion gene of a portion of the KIF5B gene and a portion of the RET gene, which is present in a portion of cancer patients, is a gene responsible for cancer. Based on this finding, detection methods of a polynucleotide as the gene and a polypeptide encoded by the polynucleotide were established. The detection methods involve detecting a fusion gene of a portion of the KIF5B gene and a portion of the RET gene, or a fusion protein encoded by such a fusion gene. The primer sets and the detection kits comprise sense primers designed from a portion encoding KIF5B and antisense primers designed from a portion encoding RET.
摘要翻译: 发现KIF5B基因的一部分的新融合基因和存在于癌症患者的一部分中的RET基因的一部分是导致癌症的基因。 基于该发现,建立了作为基因的多核苷酸的检测方法和由多核苷酸编码的多肽。 检测方法包括检测KIF5B基因的一部分和RET基因的一部分的融合基因或由这种融合基因编码的融合蛋白。 引物组和检测试剂盒包括从编码KIF5B的部分和从编码RET的部分设计的反义引物设计的有义引物。
-
公开(公告)号:US07728120B2
公开(公告)日:2010-06-01
申请号:US11845498
申请日:2007-08-27
IPC分类号: C07H21/04
CPC分类号: C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译: 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽,编码多肽的多核苷酸,包含多核苷酸的载体,包含载体的转化细胞,检测融合蛋白或多核苷酸的方法,用于筛选治疗剂的方法 癌症和治疗癌症的方法,所述方法显示为融合基因呈阳性。 此外,本发明涉及可用于检测癌症的试剂盒,引物组和探针,其对于融合基因显示为阳性。
-
公开(公告)号:US20100099658A1
公开(公告)日:2010-04-22
申请号:US12448759
申请日:2008-07-04
申请人: Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人: Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号: A61K31/397 , C07D239/72 , A61K31/497 , A61K31/517 , C07D413/02 , A61K31/5377 , C07D403/02 , A61K31/53 , C07D279/12 , A61K31/541 , A61P35/00
CPC分类号: A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译: 本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。 作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果,本发明的发明人已经发现本发明的二(芳基氨基)芳基化合物具有 对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。 这一发现导致了本发明的完成。 本发明的化合物可以用作预防和/或治疗癌症,肺癌,非小细胞肺癌,小细胞肺癌,EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物, 阳性癌症,EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。
-
公开(公告)号:US4976369A
公开(公告)日:1990-12-11
申请号:US271042
申请日:1988-11-14
CPC分类号: B65D25/32 , B65D43/0258 , B65D2101/0038 , B65D2543/00194 , B65D2543/00296 , B65D2543/00509 , B65D2543/00537 , B65D2543/00555 , B65D2543/00629 , B65D2543/00685 , B65D2543/0074 , B65D2543/00805 , B65D2543/00842
摘要: A container used for selling powders such as a washing powder and the like comprises a main body for filling the powders therein and a lid member for covering an upper opening of the main body. A band member is disposed through a score at a peripheral edge of the lid member except at a part of the peripheral edge thereof and has a peeling-off projection formed at its end. A picking-up projection is disposed at a wall of the lid member just above a space where no band member is defined. Each of these projections has a rectangular shape and has opposite surfaces. The surfaces of the peeling-off and picking-up projection are at approximately right angles to each other. These projections serve to protect one another from impacts or shocks exerted on one another. As the result, these projections are prevented them from deformation. Therefore, the container gives confidence that it can be opened by the impacts or the shocks exerted thereon at ease. After it has been opened, the fact can be confirmed because it cna hardly be opened without peeling off the band member.At least a pair of rivets is preferably formed at upper portions of pillars of a frame member of the main body because the pillars have a mechanical strength enough to hold out against a force exerted through the handle member on the rivets.
摘要翻译: 用于销售诸如洗衣粉等粉末的容器包括用于填充粉末的主体和用于覆盖主体的上部开口的盖部件。 带部件除了在其外周边缘的一部分之外还设置在盖部件的周缘处的刻痕处,并且在其端部形成有剥离突起。 拾取突起设置在盖构件的刚好在不限定带构件的空间上方的壁上。 这些突起中的每一个具有矩形形状并具有相反的表面。 剥离和拾取突起的表面彼此成大致直角。 这些预测有助于保护彼此之间的相互影响或冲击。 结果,这些突起防止它们变形。 因此,容器确信可以通过其上施加的冲击或冲击来打开它。 在打开之后,由于在没有剥离带部件的情况下几乎不打开,因此可以确认。 至少一对铆钉优选地形成在主体的框架构件的柱的上部,因为柱具有足够的机械强度以抵抗通过手柄构件施加在铆钉上的力。
-
公开(公告)号:US09029521B2
公开(公告)日:2015-05-12
申请号:US13468730
申请日:2012-05-10
IPC分类号: C07K14/435 , C12N9/12 , C07K14/47 , A61K31/506 , C12N15/113 , C12Q1/48 , C12Q1/68
CPC分类号: C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译: 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽,编码多肽的多核苷酸,包含多核苷酸的载体,包含载体的转化细胞,检测融合蛋白或多核苷酸的方法,用于筛选治疗剂的方法 癌症和治疗癌症的方法,所述方法显示为融合基因呈阳性。 此外,本发明涉及可用于检测癌症的试剂盒,引物组和探针,其对于融合基因显示为阳性。
-
-
-
-
-
-
-
-
-